Two other METTL3 inhibitors (Compound 1 and Compound 2), which were verified in a structure-guided medicinal chemistry platform, can reduce the abundance of METTL3-methylated mRNAs and suppressing the proliferation of leukemia cells both in vivo and in vitro [146]. Here, METTL3 is linked to leukemia.